Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T1 - Low dose of BI 655130
Drug: T2 - Low dose of BI 655130
Drug: T3 - High dose of BI 655130
Drug: R - Low dose of BI 655130

First Posted Date: 2018-08-06

Last Posted Date: 2024-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT03617835

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Inhaled corticosteroid

First Posted Date: 2018-08-02

Last Posted Date: 2021-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 901

Registration Number: NCT03611777

Locations: 🇪🇸
CS Las Cabezas de San Juan, Las Cabezas, Sevilla, Spain
🇪🇸
CS Virgen de la Estrella 2, Coria Del Río, Sevilla, Spain
🇪🇸
CS Puebla de Cazalla, Puebla De Cazalla, Sevilla, Spain

and more 165 locations

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517
Drug: Placebo

First Posted Date: 2018-07-31

Last Posted Date: 2024-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT03608072

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: BI 905677

First Posted Date: 2018-07-27

Last Posted Date: 2024-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT03604445

Locations: 🇳🇱
Erasmus MC Kanker Instituut, Rotterdam, Netherlands
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

and more 2 locations

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Empagliflozin
Drug: Matching placebo

First Posted Date: 2018-07-20

Last Posted Date: 2024-10-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6609

Registration Number: NCT03594110

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 234 locations

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BI 456906
Drug: Placebo

First Posted Date: 2018-07-19

Last Posted Date: 2021-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT03591718

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Germany

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Placebo

First Posted Date: 2018-07-17

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT03588390

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1265162
Drug: Placebo

First Posted Date: 2018-07-03

Last Posted Date: 2022-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT03576144

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: Placebo

First Posted Date: 2018-05-31

Last Posted Date: 2022-12-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03542344

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole IR
Drug: Pramipexole SR

First Posted Date: 2018-05-11

Last Posted Date: 2021-02-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98

Registration Number: NCT03521635

Locations: 🇨🇳
The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, China
🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
🇨🇳
Wuhan Union Hospital, Wuhan, China

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy